Prolonged Survival in Peritoneal Metastatic Appendiceal Carcinoma Patients Treated With Combined Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

被引:2
|
作者
Acs, Miklos [1 ,5 ]
Gerken, Michael [2 ]
Zustin, Jozef [3 ,4 ]
Blaj, Sebastian [1 ]
Isgandarova, Sabina [1 ]
Piso, Pompiliu [1 ]
机构
[1] Hosp Barmherzige Bru, Dept Gen & Visceral Surg, Regensburg, Germany
[2] Univ Regensburg, Inst Qual Management & Hlth Serv Res, Tumor Ctr, Regensburg, Germany
[3] Univ Med Ctr Muenster, Gerhard Domagk Inst Pathol, Munster, Germany
[4] Inst Pathol Regensburg, Regensburg, Germany
[5] Hosp Barmherzige Bru, Dept Gen & Visceral Surg, Prufeninger Str 86, D-93049 Regensburg, Germany
关键词
Appendix carcinoma; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Peritoneal metastases; LYMPH-NODE METASTASIS; SIGNET-RING CELLS; PSEUDOMYXOMA PERITONEI; MUCINOUS ADENOCARCINOMA; NEOPLASMS; CLASSIFICATION; DISSEMINATION; DIAGNOSIS; FEATURES; OUTCOMES;
D O I
10.1016/j.jss.2022.10.083
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction: Primary treatment for peritoneal dissemination of appendiceal cancer is the combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The endpoints were overall survival and evaluation of prognostic factors.Methods: Clinicopathological and treatment-related factors were obtained from a pro-spective database. A total of 84 patients, 55 (65%) primary and 29 (35%) recurrent malignant appendiceal carcinomas with synchronous and metachronous peritoneal metastases, underwent multimodal treatment between 2011 and 2021. The endpoints of the study were overall survival and evaluation of prognostic factors.Results: The median follow-up was 4.8 y; the mean age was 54.5 y (range 25-77), with a sex distribution of 69% female and 31% male. The mean peritoneal cancer index was 11.3. The proportion of mucinous, intestinal-type, signet ring cell, and goblet cell carcinoma was 56%, 23%, 11%, and 10%, respectively. The 5-y survival rate of the whole cohort was 56.7%. In primary and recurrent diseases, the overall median survival was 8.4 and 4.9 y. Signifi-cantly improved survival was detected after complete cytoreduction resection (hazard ratio [HR] for CCR-2 versus CCR-0: 9.388, 95% confidence interval [CI] 3.026-29.124, P = 0.001) and initial local operation with undelayed admission to the center (HR 0.262, 95% CI 0.089-0.773; P = 0.015). The five independent factors in Kaplan-Meier analysis and univariable Cox regression analysis associated with significant adverse survival were cancer antigen (CA) 19-9 over 37 IU/mL, signet ring cell and intestinal-type histology, positive nodal status, grading, and peritoneal cancer index >20. Neoadjuvant chemotherapy administration did not impact survival (HR 1.220, 95% CI 0.612-2.432, P = 0.571).Conclusions: With multimodal treatment, prolonged survival is attainable in stage IV pri-mary and recurrent appendiceal carcinoma with peritoneal dissemination. Direct referral to specialized centers after confirmation of peritoneal metastasis is recommended because prompt definitive treatment may significantly improve survival.& COPY; 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:839 / 852
页数:14
相关论文
共 50 条
  • [21] Prognostic significance of the immuno-peritoneal cancer index in peritoneal metastatic patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Yildirim, Yasemin
    Sokmen, Selman
    Cevlik, Ali Durubey
    Bisgin, Tayfun
    Manoglu, Berke
    Obuz, Funda
    LANGENBECKS ARCHIVES OF SURGERY, 2023, 408 (01)
  • [22] Value of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy to treat malignant peritoneal mesothelioma
    Wang, Tongfei
    Li, Haitao
    Ye, Biaofei
    Zhang, Da
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (09): : 10712 - 10720
  • [23] Predicting Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendix Adenocarcinoma
    Aziz, Omer
    Jaradat, Ihab
    Chakrabarty, Bipasha
    Selvasekar, Chelliah R.
    Fulford, Paul E.
    Saunders, Mark P.
    Renehan, Andrew G.
    Wilson, Malcolm S.
    O'Dwyer, Sarah T.
    DISEASES OF THE COLON & RECTUM, 2018, 61 (07) : 795 - 802
  • [24] Indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in elderly patients with peritoneal malignancy
    Kitai, Toshiyuki
    Yamanaka, Kenya
    Miyauchi, Yuya
    Kawashima, Masahiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (03) : 519 - 525
  • [25] Timing of Systemic Chemotherapy in Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    van Eden, Wijntje J.
    Kok, Niels F.
    Jozwiak, Katarzyna
    Lahaye, Max L.
    Beets, Geerard L.
    van Leerdam, Monique E.
    Boot, Henk
    Aalbers, Arend G.
    DISEASES OF THE COLON & RECTUM, 2017, 60 (05) : 477 - 487
  • [26] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis
    Khan, Hadi M.
    Hanif, Hamza
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (02): : 259 - 261
  • [27] Negative Impact of Systemic Therapy on Survival in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Low-Grade Metastatic Appendiceal Adenocarcinoma
    Stillman, Mason
    Somasundar, Ponnandai
    Espat, N. Joseph
    Calvino, Abdul S.
    Kwon, Steve
    ANNALS OF SURGICAL ONCOLOGY, 2025, 32 (01) : 221 - 229
  • [28] Peritoneal metastatic colorectal Cancer: cytoreductive Surgery and hyperthermic intraperitoneal Chemotherapy
    Koenigsrainer, I.
    Beckert, S.
    Bruecher, B.
    Zieker, D.
    Koenigsrainer, A.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (36) : 1811 - 1814
  • [29] Appendiceal goblet cell carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Randle, Reese W.
    Griffith, Kayla F.
    Fino, Nora F.
    Swett, Katrina R.
    Stewart, John H.
    Shen, Perry
    Levine, Edward A.
    Votanopoulos, Konstantinos I.
    JOURNAL OF SURGICAL RESEARCH, 2015, 196 (02) : 229 - 234
  • [30] Urinary tract involvement in peritoneal metastatic disease: Is this a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
    Seretis, Charalampos
    Shariff, Umar
    Youssef, Haney
    JOURNAL OF BUON, 2017, 22 (02): : 301 - 305